Shares of LDR Holding Corp. (NASDAQ:LDRH) traded down 0% on Friday . The company traded as low as $36.95 and last traded at $36.97, with a volume of 202,077 shares. The stock had previously closed at $36.98.

A number of analysts have recently weighed in on the company. Gabelli cut LDR Holding Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, June 8th. William Blair cut LDR Holding Corp. from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 7th. Royal Bank Of Canada cut LDR Holding Corp. from an “outperform” rating to a “sector perform” rating and increased their price target for the stock from $33.00 to $37.00 in a research report on Thursday, June 9th. Barclays PLC cut LDR Holding Corp. from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $27.00 to $37.00 in a research report on Friday, June 10th. Finally, Stephens cut LDR Holding Corp. from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, June 15th. Ten analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $37.73.

The stock’s 50-day moving average price is $32.04 and its 200 day moving average price is $25.21. The stock’s market capitalization is $1.08 billion.

LDR Holding Corp. (NASDAQ:LDRH) last released its earnings results on Tuesday, May 10th. The medical device company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.02. The business had revenue of $42.40 million for the quarter, compared to analysts’ expectations of $42.90 million. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) earnings per share. On average, equities research analysts predict that LDR Holding Corp. will post ($0.82) earnings per share for the current year.

In other LDR Holding Corp. news, EVP Patrick Richard sold 25,000 shares of LDR Holding Corp. stock in a transaction on Friday, April 15th. The shares were sold at an average price of $27.60, for a total transaction of $690,000.00. Following the completion of the sale, the executive vice president now owns 528,463 shares of the company’s stock, valued at approximately $14,585,578.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

A number of hedge funds have added to or reduced their stakes in the company. Sei Investments Co. raised its stake in LDR Holding Corp. by 58.1% in the fourth quarter. Sei Investments Co. now owns 84,685 shares of the medical device company’s stock worth $2,127,000 after buying an additional 31,130 shares in the last quarter. Napier Park Global Capital US LP acquired a new stake in LDR Holding Corp. during the fourth quarter worth approximately $1,148,000. CAM Group Holding A S raised its stake in LDR Holding Corp. by 42.8% in the fourth quarter. CAM Group Holding A S now owns 166,917 shares of the medical device company’s stock worth $4,191,000 after buying an additional 50,000 shares in the last quarter. California State Teachers Retirement System raised its stake in LDR Holding Corp. by 1.5% in the fourth quarter. California State Teachers Retirement System now owns 46,914 shares of the medical device company’s stock worth $1,178,000 after buying an additional 700 shares in the last quarter. Finally, Artemis Investment Management LLP raised its stake in LDR Holding Corp. by 123.2% in the fourth quarter. Artemis Investment Management LLP now owns 86,685 shares of the medical device company’s stock worth $2,175,000 after buying an additional 47,841 shares in the last quarter.

LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.